These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9533004)

  • 61. Axonal neuropathy in a patient receiving interferon-alpha therapy for chronic hepatitis C.
    Tambini R; Quattrini A; Fracassetti O; Nemni R
    J Rheumatol; 1997 Aug; 24(8):1656-7. PubMed ID: 9263170
    [No Abstract]   [Full Text] [Related]  

  • 62. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa.
    Hayasaka S; Fujii M; Yamamoto Y; Noda S; Kurome H; Sasaki M
    Br J Ophthalmol; 1995 Feb; 79(2):150-2. PubMed ID: 7696235
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin.
    Yu ML; Hou NJ; Dai CY; Chang WY; Chuang WL
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3986-7. PubMed ID: 16127091
    [No Abstract]   [Full Text] [Related]  

  • 64. [Case of hepatocellular carcinoma due to interferon therapy of chronic hepatitis C].
    Enomura H; Ogasawara M; Doi K; Endo T; Mori T; Matsuzaki O; Fujimoto Y; Takase K; Nakano T
    Nihon Naika Gakkai Zasshi; 1997 Oct; 86(10):1961-3. PubMed ID: 9445884
    [No Abstract]   [Full Text] [Related]  

  • 65. Rheumatoid arthritis following a treatment with IFN-alpha/ribavirin against HCV infection.
    Izumi Y; Komori A; Yasunaga Y; Hashimoto S; Miyashita T; Abiru S; Yatsuhashi H; Ishibashi H; Migita K
    Intern Med; 2011; 50(9):1065-8. PubMed ID: 21532235
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Minimal change disease in a patient receiving IFN-alpha therapy for chronic hepatitis C virus infection.
    Dizer U; Beker CM; Yavuz I; Ortatatli M; Ozguven V; Pahsa A
    J Interferon Cytokine Res; 2003 Jan; 23(1):51-4. PubMed ID: 12639299
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lupus syndrome, hypothyroidism and bullous skin lesions after interferon alfa therapy for hepatitis C in a haemodialysis patient.
    Pouthier D; Theissen F; Humbel RL
    Nephrol Dial Transplant; 2002 Jan; 17(1):174. PubMed ID: 11773492
    [No Abstract]   [Full Text] [Related]  

  • 68. Interferon-alpha treatment of patients with Hepatitis C: the role of a comprehensive risk-benefit assessment.
    Rifai MA; Loftis JM; Hauser P
    CNS Drugs; 2005; 19(8):719-21; author reply 721-2. PubMed ID: 16097855
    [No Abstract]   [Full Text] [Related]  

  • 69. Efficacy of human recombinant erythropoietin plus IFN-alpha in patients affected by chronic hepatitis C.
    Di Fazio I; Motta M; Musumeci S; Neri S; Pistone G; Malaguarnera M
    J Interferon Cytokine Res; 2004 Oct; 24(10):594-9. PubMed ID: 15626156
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [How should hepatitis C be monitored? Monitoring of treated hepatitis C].
    Larrey D
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S99-110. PubMed ID: 9161521
    [No Abstract]   [Full Text] [Related]  

  • 71. Lack of sustained efficacy of interferon in patients with chronic hepatitis C.
    Vento S; Concia E; Ferraro T
    N Engl J Med; 1996 May; 334(22):1479-80. PubMed ID: 8618600
    [No Abstract]   [Full Text] [Related]  

  • 72. Pericarditis due to interferon-alpha therapy during treatment for chronic hepatitis C.
    Gressens B; Gohy P
    Acta Gastroenterol Belg; 2004; 67(3):301-2. PubMed ID: 15587340
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Problem of the pathogenesis and clinical picture of meno-metrorrhagia in women with pot-tuberculous changes in the genitalia].
    Buliénko SD
    Pediatr Akus Ginekol; 1975; (5):50-2. PubMed ID: 1208173
    [No Abstract]   [Full Text] [Related]  

  • 74. [Permanent hypothyroidism after interferon-alpha treatment in chronic hepatitis C].
    Fernández Soto ML; Ventosa M; Luna V; Salmerón FJ
    Med Clin (Barc); 1996 Jun; 107(2):76-7. PubMed ID: 8753901
    [No Abstract]   [Full Text] [Related]  

  • 75. Therapy of hepatitis C: overview.
    Lindsay KL
    Hepatology; 1997 Sep; 26(3 Suppl 1):71S-77S. PubMed ID: 9305668
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Case report: silent thyroiditis developed during alpha-interferon therapy.
    Kamikubo K; Takami R; Suwa T; Kawase Y; Shiroko J; Kametani M; Tokimitsu N; Sakata S
    Am J Med Sci; 1993 Sep; 306(3):174-6. PubMed ID: 8128980
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interferon-induced hypopituitarism.
    Concha LB; Carlson HE; Heimann A; Lake-Bakaar GV; Paal AF
    Am J Med; 2003 Feb; 114(2):161-3. PubMed ID: 12586243
    [No Abstract]   [Full Text] [Related]  

  • 78. New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C.
    Kawazoe T; Araki M; Lin Y; Ogawa M; Okamoto T; Yamamura T; Wakakura M; Murata M
    Intern Med; 2012; 51(18):2625-9. PubMed ID: 22989839
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C.
    Rostaing L; Modesto A; Baron E; Cisterne JM; Chabannier MH; Durand D
    Nephron; 1996; 74(3):512-6. PubMed ID: 8938673
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New treatment for hepatitis C.
    Williams CN
    Can J Gastroenterol; 1999; 13(1):19-20. PubMed ID: 10099812
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.